Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects

Deleterious variants in the BRCA1/BRCA2 genes and homologous recombination deficiency (HRD) status are considered strong predictors of response to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). The introduction of PARPi in clinical practice for the treatment of patients with advanced ovaria...

Full description

Bibliographic Details
Main Authors: Ana Peixoto, Pedro Pinto, Joana Guerra, Manuela Pinheiro, Catarina Santos, Carla Pinto, Rui Santos, Carla Escudeiro, Carla Bartosch, Rita Canário, Ana Barbosa, Alfredo Gouveia, Almerinda Petiz, Miguel Henriques Abreu, Susana Sousa, Deolinda Pereira, João Silva, Manuel R. Teixeira
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Oncology
Subjects:
BRCA1/BRCA2
ovarian cancer
PARPi
NGS
founder variants
tumor testing
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01318/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01318/full

Similar Items